Sites of phosphorylation in tau and factors affecting their regulation
The DOI matches its Crossref record.
Abstract
The microtubule-associated protein, tau, is the principal component of paired helical filaments (PHFs) in Alzheimer's disease. PHF-tau is highly phosphorylated and a total of 25 sites of phosphorylation have so far been identified. Many of these sites are serine or threonine residues that are immediately followed in the sequence by proline residues, and hence are candidate phosphorylation sites for proline-directed kinases. In vitro, glycogen synthase kinase-3 (GSK-3), extracellular signal-related kinase-1 and -2, and mitogen-activated protein kinases, p38 kinase and c-jun N-terminal kinase, all phosphorylate many of these sites, although with different efficiencies for particular sites. Phosphorylation studies in transfected cells and neurons show that GSK-3 phosphorylates tau more extensively than do these other proline-directed kinases. Mutations in tau have been shown to affect in vitro phosphorylation of tau by GSK-3. The Arg406-->Trp (R406W) tau mutation also affects tau phosphorylation in cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The GSK3 hypothesis of Alzheimer’s disease
Hooper, C., Killick, R., & Lovestone, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05194.x · Cited by 1,191
Self-citationTau pathology in Alzheimer disease and other tauopathies
Iqbal, K., del C. Alonso, A., Chen, S., Chohan, M. O., El-Akkad, E., Gong, C.-X., Khatoon, S., Li, B., Liu, F., Rahman, A., et al. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.09.008 · Cited by 1,037
Tau phosphorylation: the therapeutic challenge for neurodegenerative disease
Hanger, D. P., Anderton, B. H., & Noble, W. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.01.003 · Cited by 965
Self-citationMechanisms of tau-induced neurodegeneration
Iqbal, K., Liu, F., Gong, C.-X., Alonso, A. D. C., & Grundke-Iqbal, I. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0486-3 · Cited by 628
Tau phosphorylation in neuronal cell function and dysfunction
Johnson, G. V. W., & Stoothoff, W. H. (2004) · Journal of Cell Science · doi:10.1242/jcs.01558 · Cited by 624
Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases
Mazanetz, M. P., & Fischer, P. M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2111 · Cited by 459
Tau phosphorylation: physiological and pathological consequences
Stoothoff, W. H., & Johnson, G. V. W. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.06.017 · Cited by 442
Ferrer, I., Gomez-Isla, T., Puig, B., Freixes, M., Ribe, E., Dalfo, E., & Avila, J. (2005) · Current Alzheimer Research · doi:10.2174/1567205052772713 · Cited by 304
Bachstetter, A. D., Xing, B., de Almeida, L., Dimayuga, E. R., Watterson, D. M., & Van Eldik, L. J. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-79 · Cited by 282
“Particularly relevant to AD, for example, are reports showing that activation of neuronal p38 MAPK contributes to Ab-induced impairment of cortical LTP [46], and that p38 MAPK can phosphorylate tau in vitro at sites seen in AD brain [47,48].”
Rockenstein, E., Torrance, M., Adame, A., Mante, M., Bar-on, P., Rose, J. B., Crews, L., & Masliah, E. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4321-06.2007 · Cited by 288
Ding, Y., Qiao, A., Wang, Z., Goodwin, J. S., Lee, E.-S., Block, M. L., Allsbrook, M., McDonald, M. P., & Fan, G.-H. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3153-08.2008 · Cited by 269
Giovinazzo, D., Bursac, B., Sbodio, J. I., Nalluru, S., Vignane, T., Snowman, A. M., Albacarys, L. M., Sedlak, T. W., Torregrossa, R., Whiteman, M., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2017225118 · Cited by 270
Gao, C., Hölscher, C., Liu, Y., & Li, L. (2012) · revneuro · doi:10.1515/rns.2011.061 · Cited by 164
“GSK3 α and GSK3 β are involved in a variety of cellular processes including glycogen metabolism (Welsh and Proud , 1993 ), gene transcription (Troussard et al. , 1999 ), apoptosis (Turenne and Price , 2001 ) and microtubule stability (Anderton et al. , 2001 ; Brion et al. , 2001 ).”
BackgroundThe role of miR-103 and miR-107 in regulation of CDK5R1 expression and in cellular migration
Moncini, S., Salvi, A., Zuccotti, P., Viero, G., Quattrone, A., Barlati, S., De Petro, G., Venturin, M., & Riva, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020038 · Cited by 104
Mediators of tau phosphorylation in the pathogenesis of Alzheimer’s disease
Hanger, D. P., Seereeram, A., & Noble, W. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.104 · Cited by 98
Self-citationKinase activities increase during the development of tauopathy in htau mice
Kelleher, I., Garwood, C., Hanger, D. P., Anderton, B. H., & Noble, W. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04930.x · Cited by 78
Self-citationBrain insulin resistance triggers early onset Alzheimer disease in Down syndrome
Tramutola, A., Lanzillotta, C., Di Domenico, F., Head, E., Butterfield, D. A., Perluigi, M., & Barone, E. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104772 · Cited by 73
Metadata
- Authors
- Anderton, B. H., Betts, J., Blackstock, W. P., Brion, J.-P., Chapman, S., Connell, J., Dayanandan, R., Gallo, J.-M., Gibb, G., Hanger, D. P., Hutton, M., Kardalinou, E., Leroy, K., Lovestone, S., Mack, T., Reynolds, C. H., & Van Slegtenhorst, M.
- Venue
- Biochemical Society Symposia
- Publisher
- Portland Press Ltd.
- Published
- 2001-02-01
- Volume
- 67
- Issue
- 67
- Pages
- 73-80
- ISSN
- 0067-8694 (ISSN-L)
- 1744-1439
- OpenAlex
- W1540112213
- Cited by
- 98
- References
- 0
- FWCI
- 3.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.